Skip to Content

Notice

EVSCO Pharmaceuticals, an Affiliate of IGI, Inc.; Withdrawal of Approval of NADAs

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is withdrawing approval of two new animal drug applications (NADAs) held by EVSCO Pharmaceuticals, an Affiliate of IGI, Inc. In a final rule published elsewhere in this issue of the Federal Register, FDA is amending the animal drug regulations to remove the portions reflecting approval of the NADAs because these products are no longer manufactured or marketed.

DATES:

Withdrawal of approval is effective August 27, 2001.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Pamela K. Esposito, Center for Veterinary Medicine (HFV-210), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-5593.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

EVSCO Pharmaceuticals, an Affiliate of IGI, Inc., Box 209, Harding Hwy., Buena, NJ 08310, has requested that FDA withdraw approval of NADA 32-984 for Cerumite (chloramphenicol, prednisolone, tetracaine, and squalane) topical suspension, and NADA 55-005 for Liquichlor with Cerumene (squalane, pyrethrins, and piperonyl butoxide) topical suspension because the products are no longer manufactured or marketed.

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 Withdrawal of approval of applications (21 CFR 514.115), notice is given that approval of NADAs 32-984 and 55-005 and all supplements and amendments are withdrawn effective August 27, 2001.

In a final rule published elsewhere in this issue of the Federal Register, the agency is amending the animal drug regulations to reflect the withdrawal of approval of these NADAs.

Start Signature

Dated: August 6, 2001.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 01-20574 Filed 8-14-01; 8:45 am]

BILLING CODE 4160-01-S